BioMarin to buy Prosensa in $840 mln deal

Nov 24 (Reuters) - BioMarin Pharmaceuticals Inc said it would buy Dutch drug developer Prosensa Holding NV for about $840 million including milestone payments, aiming to add to its portfolio of drugs to treat rare diseases.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.